A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

BACKGROUND: In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the addition of paclitaxel to platinum treatment has been shown to improve survival but at the cost of significant neuropathy. In the first line setting, the carboplatin-docetaxel combination was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yun, Herrstedt, Jørn, Havsteen, Hanne, DePoint Christensen, Rene, Mirza, Mansoor Raza, Lund, Bente, Maenpaa, Johanna, Kristensen, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295274/
https://www.ncbi.nlm.nih.gov/pubmed/25494701
http://dx.doi.org/10.1186/1471-2407-14-937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295274/
https://www.ncbi.nlm.nih.gov/pubmed/25494701
http://dx.doi.org/10.1186/1471-2407-14-937

Ejemplares similares